← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Neuraminidase inhibitors
laninamivir
J05AH04
Forms & Strengths
- Inhalation powder: 20 mg/actuation in a device
Adult Dosing
- Treatment of influenza A and B: 40 mg (two 20-mg blisters) as a single inhaled dose
- Prophylaxis of influenza: 20 mg as a single inhaled dose (alternative regimen)
Pediatric Dosing
- Children 10 years and older: 40 mg as a single inhaled dose
- Children under 10 years: 20 mg as a single inhaled dose
- Safety and efficacy in infants under 1 year are not well established
Indications
- Treatment of influenza virus types A and B infections
- Prophylaxis of influenza virus infections
Mechanism of Action
- Neuraminidase inhibitor acting as a transition-state analogue
- Cleaves sialic acid residues on viral surfaces, preventing release of progeny influenza virions
- Prodrug hydrolyzed to active form (laninamivir) within the respiratory tract, providing prolonged local retention
Contraindications
- Hypersensitivity to laninamivir or any component of the formulation
Adverse Reactions
- Diarrhea
- Nausea
- Headache
- Nasopharyngitis
- Abnormal behavior and neuropsychiatric events (rare, primarily in pediatric patients)
Drug Interactions
- Inactivated influenza vaccines: May be administered concurrently; live attenuated influenza vaccine (LAIV) efficacy may be reduced by antiviral drugs
Curated Content: Needs Vetting Before Put to Clinical Use